The switch from subcutaneous deferoxamine to oral deferasirox was one of the most impactful advances in thalassemia and SCD care. This post summarises why once-daily oral chelation delivers real-world benefit.
1. Adherence #
Adherence is the single most important determinant of chelation effectiveness. Once-daily oral dosing - taken with a morning drink - fits around a patient's life. In contrast, 8-12 hour overnight subcutaneous infusions 5-7 nights weekly are historically associated with patient burn-out and non-adherence, particularly in adolescents.
2. Quality of Life #
- No infusion pumps, needles or site reactions
- Reduced caregiver burden (especially in pediatric care)
- Fewer missed school or work days
- Normalised daily routine
3. Real-World Iron Burden Reduction #
Real-world registries (EPIC and regional data) show that deferasirox delivers meaningful ferritin and LIC reductions across diverse populations - including patients who struggled with parenteral chelation.
4. Pediatric Acceptability #
Dispersible tablets can be dispersed in water, orange juice or apple juice - typically acceptable even to younger children. Fine-grained weight-based dosing is supported by 100 mg and 125 mg unit sizes.
5. Psychosocial Benefits #
Transitioning to oral chelation often improves patient sense-of-control and self-management - themselves associated with better adherence and mental-health outcomes in chronic disease.
6. Clinical Considerations #
Oral chelation is not without considerations - renal and hepatic monitoring, GI tolerability, rare serious cutaneous reactions (SCAR) - and patients must be counselled. The benefit-risk balance in adherent patients is favourable.
DEFRATAJ - once-daily Deferasirox dispersible tablets in 5 strengths.